Cassava Sciences (SAVA) Projected to Post Quarterly Earnings on Wednesday

Cassava Sciences (NASDAQ:SAVA) is projected to announce its earnings results before the market opens on Wednesday, February 26th. Analysts expect the company to announce earnings of ($0.99) per share for the quarter.

Cassava Sciences Stock Down 2.0 %

Shares of NASDAQ:SAVA opened at $2.50 on Tuesday. The company’s fifty day moving average is $2.53 and its two-hundred day moving average is $16.23. Cassava Sciences has a 12-month low of $2.23 and a 12-month high of $42.20. The company has a market cap of $120.28 million, a P/E ratio of -1.81 and a beta of -0.95.

Insider Buying and Selling at Cassava Sciences

In other news, CFO Eric Schoen sold 59,800 shares of the business’s stock in a transaction on Friday, November 29th. The shares were sold at an average price of $3.86, for a total transaction of $230,828.00. Following the transaction, the chief financial officer now directly owns 11,500 shares in the company, valued at $44,390. The trade was a 83.87 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 12.20% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright downgraded shares of Cassava Sciences from a “buy” rating to a “neutral” rating and set a $116.00 target price on the stock. in a research note on Tuesday, November 26th.

Cassava Sciences Company Profile

Cassava Sciences, Inc, a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease.